List view / Grid view
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
Despite many companies considering digital transformation a top priority, research shows that 70% of digital transformation initiatives fail. In this ebook, we explore why and how the right approach can see your organisation succeed.
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
